Table 3.

UAS7 at first and second cycles of omalizumab administration

Omalizumab administration	Initial therapy	Retreatment therapy	p value
Patients, n (%)	18 (100)	3 (17.6)	–
7-day Urticaria Activity Score (UAS7), mean, standard deviation (range)
Baseline	27.3 ± 7.4 (15–38)	19.3 ± 4.9 (16–25)	0.091
Week 1	18.1 ± 7.4 (3–38)	2.3 ± 2.5 (0–5)	0.002
Week 4	16.1 ± 10.5 (0–36)	1.3 ± 1.2 (0–2)	0.028
Week 12	10.2 ± 12.6 (0–39)	0.7 ± 1.2 (0–2)	0.215
Week 16	8.3 ± 10.6 (0–33)	1.7 ± 1.5 (0–3)	0.306
Week 20	6.6 ± 8.5 (0–22)	0	0.207
Week 24	8.3 ± 12.4 (0–35)	–	–
Drop out, n (%)	1 (5.6)	0	–
Response based on UAS7 at end of treatment, n (%)a
Complete (UAS7 = 0)	10 (58.8)	3 (100)	–
Good (1 ≤ UAS7 ≤ 6)	1 (5.9)	0	–
Partial (6 < UAS7 < UAS7 at baseline)	4 (23.5)	0	–
No response (UAS7 ≥ UAS7 at baseline)	2 (11.8)	0	–

^a17 patients completed the treatment